Document 0027
 DOCN  M9480027
 TI    Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate
       immunogens.
 DT    9410
 AU    Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S;
       Rivetna M; Rusiecki VK; Sugg EE; et al; Department of Virus and Cell
       Biology, Merck Research; Laboratories, West Point, PA 19486.
 SO    Vaccine. 1994 Apr;12(5):445-51. Unique Identifier : AIDSLINE
       MED/94295251
 AB    A successful prophylactic human immunodeficiency virus type 1 (HIV-1)
       vaccine must elicit an immune response that will prevent establishment
       of the persistent viral infection. The only response shown to be
       effective in this regard is virus-neutralizing antibody directed against
       the viral gp120 hypervariable V3-loop region. Conjugate immunogens,
       containing cyclic peptides representing the V3 determinant covalently
       bound to a carrier protein, were capable of eliciting virus-neutralizing
       antibodies. The consistency of the response was related to peptide size.
       The smaller cyclic peptides, expressing relatively conserved sequences
       from the V3-loop apex, were poor inducers of neutralizing activity. In
       contrast, the largest cyclic peptides mediated neutralizing responses
       that were similar to those observed and previously reported for intact
       gp120 immunogens. A cyclic synthetic peptide expressing most of the
       prototypic HIV-1 MN variant V3 determinant warrants further study as a
       potentially effective vaccine immunogen.
 DE    Amino Acid Sequence  Animal  AIDS Vaccines/*IMMUNOLOGY  Comparative
       Study  Enzyme-Linked Immunosorbent Assay  Haplorhini  HIV
       Antibodies/BIOSYNTHESIS  HIV Envelope Protein gp120/*IMMUNOLOGY
       HIV-1/*IMMUNOLOGY  Molecular Sequence Data  Neutralization Tests
       Peptide Fragments/CHEMICAL SYNTHESIS/*IMMUNOLOGY  Peptides,
       Cyclic/CHEMICAL SYNTHESIS/IMMUNOLOGY  Rabbits  Vaccines,
       Conjugate/IMMUNOLOGY  Vaccines, Synthetic/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).